Polyomaviruses KI and WU in Immunocompromised Patients with Respiratory Disease

Thomas Mourez, Anne Bergeron, Patricia Ribaud, Catherine Scieux, Régis Peffault de Latour, Abdellatif Tazi, Gérard Socié, François Simon, and Jérôme LeGoff

Polyomaviruses KI (KIPyV) and WU (WUPyV) were recently identified, mainly in respiratory specimens from children. Among 200 patients with respiratory disorders admitted to Saint Louis Hospital, Paris, France, KIPyV was detected in 8% and WUPyV in 1%. KIPyV was significantly more frequent among human stem cell transplant patients (17.8% vs. 5.1%; p = 0.01).

Recently, 2 new, distinct polyomaviruses (PyVs), KI (KIPyV) and WU (WUPyV), were identified in respiratory specimens, mainly from children <5 years of age with respiratory tract infections. The first retrospective studies of respiratory specimens in Sweden and Australia showed a KIPyV prevalence of 1% and 2.5%, respectively (1,2). Studies conducted in Australia and the United States showed a WUPyV prevalence in respiratory specimens of 3% and 0.7%, respectively (3). Further studies conducted in Canada and South Korea have shown similar frequencies (4,5). In this study, we examined the prevalence of KIPyV and WUPyV in immunocompromised patients with suspected respiratory tract infections.

The Study

From January through June 2007, 265 respiratory samples were received in the laboratory of Saint Louis Hospital, Paris: 154 nasal aspirates (NA) and 111 bronchoalveolar lavage (BAL) specimens collected from 200 patients with suspected upper or lower respiratory tract infections. This hospital specializes in the management of immunocompromised patients. Respiratory samples were collected for the diagnosis of acute respiratory illness; 89% of samples were from immunocompromised patients. Their median age was 46 years (range 3.6–85.3 years). Given the observational nature of the study, French law did not require ethical approval or informed consent.

DOI: 10.3201/1501.080758

The specimens were routinely tested for influenza A and B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2, and 3 by immunofluorescence assay (Imagen; DakoCytomation, Trappes, France). Specimens positive for KIPyV or WUPyV were tested for adenoviruses; human bocavirus; human rhinoviruses; human metapneumovirus; human coronaviruses OC43, 229E, NL63, HKU1; and human PyVs BK and JC by using PCR methods (6-11). Total nucleic acid was extracted from 200 µL of NA, BAL, or stool specimens by using the EasyMag System (bio-Mérieux, Marcy l'Etoile, France). KIPyV was detected with an in-house real-time PCR assay targeting the VP1 gene. The primers and hydrolysis probe were designed by using Primer Express 3.0 software (Applied Biosystems, Foster City, CA, USA). The final reaction volume was 25 µL and contained 12.5 pmol of SLKI-VP1s (5'-GGAAATACAGCTGCTCAGGAT-3') and SLKI-VP1as (5'-CTTTGATACTTGAACCGCTTTCCTT-3'), 6.25 pmol corresponding probe SLKI-VP1PR (5'-6FAM-C of GTGACCCCACCCCTCATTACTGGTC-TAMRA-3'), 12.5 µL of TaqMan Universal Master Mix (Applied Biosystems), and 5 µL of DNA extract. The reaction was run on a 7500 Real-Time PCR System (Applied Biosystems). The specificity of positive specimens was confirmed by using PCR and nested PCR with primers POLVP1-39F/POLVP1-363R and POLVP1-118F/POLVP1-324R, as described (1). The PCR products were then sequenced and compared with the previously described sequences from Sweden and Australia (GenBank accession nos. EF127906, EF127907, EF127908, EF520287, EF520288, and EF520289). WUPyV was detected by PCR as described (3). PCR products with the expected molecular weights were sequenced by using primers AG0044 and AG0045 and compared to published sequences (GenBank accession nos. EF444550, EF444551, EF444552, EF444553, and EF444554) (3).

KIPyV was detected in 17 (6.5%) of the 265 respiratory samples and in 16 (8.0%) of the 200 patients. All cases were confirmed by a nested PCR targeting another region of the VP1 gene. Twelve of the 17 PCR products were successfully sequenced, and all shared 100% homology with published sequences. WUPyV was detected in only 2 patients (1.0%). Genome sequencing showed 98% homology with reported WUPyV sequences.

Six KIPyV-positive patients (37.5%) had co-infections with other respiratory viruses, and 2 of them (12.5%) had a pulmonary bacterial infection (online Appendix Table, available from www.cdc.gov/EID/content/15/1/107-appT. htm). One WUPyV-infected patient who exhibited acute respiratory failure had concomitant pneumonia caused by *Pseudomonas aeruginosa* infection. None of the 15 patients who were positive for KIPyV or WUPyV and tested for fungi had respiratory or blood samples positive for *Aspergillus* spp.

Author affiliation: Hôpital Saint Louis, Paris, France

DISPATCHES

The clinical characteristics of the patients with KIPyV or WUPyV infection and their general outcome until December 2007 are given in the online Appendix Table. All but 3 had well-identified systemic immunosuppression. However, all had severe coexisting conditions. All KIPyV- and WUPyVpositive patients had acute respiratory disorders.

Eight KIPyV-positive patients had received allogeneic stem cell transplants; 5 of them had exhibited profound neutropenia in the 2 weeks before the respiratory sample was found to be positive. The detection of KIPyV was significantly more frequent among hematopoietic stem cell transplant (HSCT) recipients than among other patients (17.8% [8/45] vs. 5.1% [8/155], p = 0.01) (Table). Lung or sinus imaging was assessed by computed tomography scan for 12 KIPyV-positive patients. Lung parenchyma abnormalities were noted in 9 patients, and sinusitis was diagnosed for 2 patients.

Taking into consideration both the frequency of digestive symptoms in our patients and the former published detection of KIPyV in a stool sample, we looked for KIPyV infection in the available stool samples while the respiratory samples were being assessed for KIPyV (*I*). Strikingly, 3 of 4 samples tested were positive for KIPyV (with cycle threshold values of 35.0, 38.3, and 40.3). All were collected from HSCT recipients. In addition, 1 HSCT patient who experienced diarrhea demonstrated persistent excretion of KIPyV in 9 consecutive stool specimens collected between June and the end of November 2007 (data not shown).

Conclusions

This study shows the prevalence of KIPyV and WUPyV among immunocompromised patients with respiratory disorders. Previously, these 2 viruses had been observed mainly in young children (1-3). Of the few adult patients with KIPyV or WUPyV infection mentioned in these studies, most were immunocompromised (3,12).

Considering the seemingly higher prevalence of KIPvV in our population (8%), immunocompromised patients may be more susceptible to this PyV, as they are to JC and BK viruses (13-15). Results from previous reports suggest a similar frequency of both KIPyV and WUPyV infections being found in respiratory specimens, ranging from 1% to 3%. In contrast, in our series, we found a likely difference between the prevalence of KIPyV (8%) and WUPyV (1%), which suggests that the replication or reactivation of the 2 viruses in the respiratory tract may differ between immunocompromised and immunocompetent patients. However, this difference requires further investigation, in particular, by using similar real-time PCR assays. Notably, a significantly higher prevalence of KIPyV infection was found among HSCT patients, which suggests that a profound T-cell deficiency may be a factor in facilitating KIPyV replication.

Table. Frequency of KI polyomavirus detection in respiratory samples*

	KIV detection in respiratory samples, no. (%)								
Sample source	Positive	Negative	Total						
HSCT patients	8 (17.8)†	37 (82.2)	45						
Other patients	8 (5.2)	147 (94.8)	155						
Total	16	184	200						
*HSCT, hematopoietic stem cell transplantation. tv^2 tost with Vatas correction: $p = 0.01$									

As reported in other populations, our patients who yielded positive specimens for KIPyV or WUPyV had conditions ranging from a common cold to acute respiratory distress that required invasive ventilation. Respiratory coinfections, observed in other studies, had likely accounted for at least some clinical features. In the 7 of our patients in whom KIPyV was the sole pathogen detected in the respiratory tract, despite comprehensive screening for viruses, bacteria, parasites, and fungi, clinical and radiographic patterns were varied. Some of the patients had only upper respiratory tract infections, notably sinusitis, whereas others had lung parenchyma abnormalities as defined by computed tomographic scan imaging. However, due to the retrospective nature of the study, and therefore the lack of a control group of immunocompromised patients without respiratory symptoms, the association of KIPyV infection with the occurrence of respiratory disease cannot be stated definitively.

In conclusion, the seemingly higher frequency of KIPyV shedding in immunocompromised patients (as observed with other PyVs) and the detection of KIPyV as a single pathogen in respiratory disease (e.g., as cytomegalovirus recurrence can lead to pneumonia in immunocompromised patients) together support a reactivation hypothesis. Nevertheless, a reinfection hypothesis cannot be excluded due to immunocompromised patients' increased risk of acquiring viral infection from exogenous sources

Controlled prospective studies of KIPyV shedding before and during immunosuppression will help determine the pathogenic role of this virus. The clinical implication of KIPyV detection in stools and the mechanisms underlying the concomitant presence in gastrointestinal and respiratory tracts also deserve further analysis.

Acknowledgments

We thank F. Freymuth, P. Lebon, and A. Vabret for advice and technical assistance and for providing positive virus controls.

Dr Mourez is a virologist in the Laboratory of Microbiology, Saint Louis University Hospital, Paris. His research interests include the development of tests for the diagnosis of emerging respiratory viruses and the study of the circulation and molecular analysis of human respiratory viruses in pediatric and immunocompromised patients.

Polyomaviruses in Immunocompromised Patients

References

- Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, Persson MA, et al. Identification of a third human polyomavirus. J Virol. 2007;81:4130–6. DOI: 10.1128/JVI.00028-07
- Bialasiewicz S, Whiley DM, Lambert SB, Wang D, Nissen MD, Sloots TP. A newly reported human polyomavirus, KI virus, is present in the respiratory tract of Australian children. J Clin Virol. 2007;40:15–8. DOI: 10.1016/j.jcv.2007.07.001
- Gaynor AM, Nissen MD, Whiley DM, Mackay IM, Lambert SB, Wu G, et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog. 2007;3:e64. DOI: 10.1371/journal.ppat.0030064
- Abed Y, Wang D, Boivin G. WU polyomavirus in children, Canada. Emerg Infect Dis. 2007;13:1939–41.
- Han TH, Chung JY, Koo JW, Kim SW, Hwang ES. WU polyomavirus in children with acute lower respiratory tract infections, South Korea. Emerg Infect Dis. 2007;13:1766–8.
- Robin M, Marque-Juillet S, Scieux C, Peffault de Latour R, Ferry C, Rocha V, et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica. 2007;92:1254–7. DOI: 10.3324/haematol.11279
- Savolainen C, Mulders MN, Hovi T. Phylogenetic analysis of rhinovirus isolates collected during successive epidemic seasons. Virus Res. 2002;85:41–6. DOI: 10.1016/S0168-1702(02)00016-3
- Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A. 2005;102:12891–6. DOI: 10.1073/pnas.0504666102
- Bellau-Pujol S, Vabret A, Legrand L, Dina J, Gouarin S, Petitjean-Lecherbonnier J, et al. Development of three multiplex RT-PCR assays for the detection of 12 respiratory RNA viruses. J Virol Methods. 2005;126:53–63. DOI: 10.1016/j.jviromet.2005.01.020

- 10. Vabret A, Dina J, Gouarin S, Petitjean J, Corbet S, Freymuth F. Detection of the new human coronavirus HKU1: a report of 6 cases. Clin Infect Dis. 2006;42:634–9. DOI: 10.1086/500136
- Herman J, Van Ranst M, Snoeck R, Beuselinck K, Lerut E, Van Damme-Lombaerts R. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique. Pediatr Transplant. 2004;8:485–92. DOI: 10.1111/j.1399-3046.2004.00211.x
- Norja P, Ubillos I, Templeton K, Simmonds P. No evidence for an association between infections with WU and KI polyomaviruses and respiratory disease. J Clin Virol. 2007;40:307–11. Epub 2007 Nov 7. DOI: 10.1016/j.jcv.2007.09.008
- Shapiro S, Robin M, Esperou H, Devergie A, Rocha V, Garnier F, et al. Polyomavirus nephropathy in the native kidneys of an unrelated cord blood transplant recipient followed by a disseminated polyomavirus infection. Transplantation. 2006;82:292–3. DOI: 10.1097/01. tp.0000226172.68372.f9
- Hirsch HH. BK virus: opportunity makes a pathogen. Clin Infect Dis. 2005;41:354–60. DOI: 10.1086/431488
- Drachenberg CB, Hirsch HH, Papadimitriou JC, Gosert R, Wali RK, Munivenkatappa R, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation. 2007;84:323–30. DOI: 10.1097/01. tp.0000269706.59977.a5

Address for correspondence: Jérôme LeGoff, Laboratoire de Microbiologie, Hôpital Saint-Louis 1, Ave Claude Vellefaux 75010 Paris, France; email: jerome.le-goff@sls.aphp.fr

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.

EMERGING Full text free online at www.cdc.gov/eid	
The print journal is available at no charge to public health professionals	
YES, I would like to receive Emerging Infectious Diseases.	
Please print your name and business address in the box and return by fax to 404-639-1954 or mail to EID Editor CDC/NCID/MS D61 1600 Clifton Road, NE Atlanta, GA 30333	EID Onling
Moving? Please give us your new address (in the box) and print the number of your old mailing label here	www.cdc.gov/eid

Publisher: CDC; Journal: Emerging Infectious Diseases Article Type: Dispatch; Volume: ; Issue: ; Year: ; Article ID: 08-0758 DOI: ; TOC Head:

Appendix Table. Clinical characteristics and outcome of patients with KI or WU polyomavirus identified during the study*

Sample no.	Age. y/sex	Date sample collected	Sample type	Ct value	Underlying disease	Type of transplant/date	Neutropenia in the past 2 weeks?†	Immunosuppressive treatment	Respiratory symptoms	Systemic symptoms	Digestive symptoms	Lung CT scan/sinus CT scan	Respiratory co- infections	Outcome of acute respiratory event	General outcome
KI polyomav	irus														
SL2-39	29/F	2007 Jan 26	BAL	35.9	Unclassified immune deficiency	None	No	No	Cough, dyspnea	Fever, myalgia	None	Bibasal alveolar opacities/ND	Haemophilus influenzae	Cured	Alive 2007 Jun 21
SL2-47	27/F	2007 Jan 27	NPA	37.3	ALL	Unrelated bone marrow/2007 Jan 26	Yes	Methotrexate Cyclosporine	Epistaxis	Fever	None	ND/bilateral maxillary sinusitis	None	Cured	Alive 2007 Sep 05
SL2-78 SL3-27	14/M	2007 Feb 5 2007 Feb 19	NPA NPA	39.4 38.8	T-cell ALL	Genoidentical bone marrow/2007 Feb 15	Yes	Cyclosporine	Cough, hypoxemia	Fever	None‡	Diffuse centro- lobular micronodules/ND	hRV, HCoV- NL63 hRV, hMPV	Cured	Alive 2007 Dec 6
SL3-09	73/F	2007 Feb 13	NPA	37.0	Chronic cardiac failure	None	No	No	Cough, dyspnea, hypoxemia	Fever	Abdominal pain	ND (normal chest radiograph)/ND	None	Cured	Lost to follow-up
SL3-14	39/M	2007 Feb 14	NPA	35.4	Chronic EBV- related lymphoid proliferation	None	No	No	Cough, rhinorrhea, pharyngitis	None	None	Diffuse right ground glass opacities/ND	hRV	Cured	Alive 2007 Oct 11
SL3-83	36/M	2007 Mar 16	NPA	21.5	ALL, Grade 4 GVHD	Genoidentical bone marrow/ 2008 Feb 8	No	Prednisone (1.5 mg/kg/d), cvclosporine	Cough	Fever, shivers	Diarrhea, abdominal pain±	Normal/bilateral maxillary sinusitis	None	NA	Died 2007 Apr 18§
SL3-84	72/M	2007 Mar 16	NPA	35.7	Chronic renal insufficiency, bronchiectasies	Kidney/2005 Oct	No	Mycophenolate mofetil, cyclosporine	Cough, sputum, rhinorrhea	Fever, myalgia	None	Thickened bronchiectasis/ND	hRV	Cured	Alive 2007 Jun 25
SL3-85	72/F	2007 Mar 16	NPA	37.0	Severe respiratory insufficiency	None	No	Prednisone (0.5 mg/kg/d)	Dyspnea, hypoxemia, rhinorrhea, pharyngitis	None	None	ND (normal chest radiograph)/ND	IFA	Cured	Alive 2007 Aug 10
SL3-97	59/M	2007 Mar 22	NPA	34.0	Severe respiratory insufficiency	None	No	No	Dyspnea, sputum, hypoxemia	None	None	ND (normal chest radiograph)/ND	HCoV-NL63	Cured	Alive 2007 Jul 17
SL3-99	26/M	2007 Mar 26	NPA	40.0	Aplastic anemia, dyskeratosis	Unrelated cord blood/2007 Feb 13	Yes	Prednisone (0.75 mg/kg/d)	None	Fever, shivers	None	Diffuse left nodules/ND	JCV, BKV, Staphylococcus haemolvticus	Progression¶	Died 2007 May 25#
SL4-11	19/F	2007 Apr 3	NPA	25.0	ALL	2 unrelated blood cords/2006 Sep 28	No	Prednisone (10 mg/d), cyclosporine	Cough, sputum	Fever	None	ND (normal chest radiograph)/ND	None	Cured	Alive 2007 Sep 11
SL4-14	5/F	2007 Apr 2	NPA	36.3	ALL	None	Yes	No	Rhinorrhea	Fever	Diarrhea	ND/ND	None	Cured	Alive 2007 Oct 10
SL4-17	27/M	2007 Apr 2	NPA	38.9	AML	Unrelated peripheral blood stem cell/2006 May 2	No	Prednisone (1 mg/kg/d)	Dyspnea	None	None	Diffuse alveolar opacities/ND*	None	Cured	<mark>??</mark>
SL4-39	28/F	2007 Apr 17	BAL	38.1	Systemic lupus erythematosus	None	No	No	Cough, sputum	None	None	Diffuse air trapping/ND	None o	Cured	Alive 2007 Jun 8
SL4-93	42/M	2007 Jun 5	NPA	29.9	AML, chronic extensive GVHD	Unrelated bone marrow/2007 Jan 18	No	Prednisone (0.25 mg/kg/d), cyclosporine	Śputum	Fever	None	Apical right alveolar opacity/ND	None	Cured	Alive 2007 Sep 19

Publisher: CDC; Journal: Emerging Infectious Diseases

Article Type: Dispatch; Volume: ; Issue: ; Year: ; Article ID: 08-0758

DOI., $IOC IICau$.	DOI:	;	TOC Head:
---------------------	------	---	-----------

SL4-94	17/M	2007 Jun 5	NPA	25.6	T-cell ALL	2 unrelated blood cords/ 2007 May 3	Yes	Prednisone (1 mg/kg/d)	Dyspnea	None	None §	Diffuse centro- lobular nodules/ND	PIV	Cured	Alive 2007 Nov 6
WU polyoma	virus	0007 has 0			T U h h	News	NI-	NI-	Onuch	N	N	Difference bereiten	Nama	Durantesian	Allan 0007
SL4-89	46/IVI	2007 Jun 2	NPA		I-cell lympnoma	None	NO	INO	dyspnea	None	None	opacities and nodules/ND**	None	of lung lymphoma	Oct
SL4-100	44/F	2007 Jun 11	BAL		AML	None	No	No	NA (MV)	Fever	None	ND (bilateral opacities on chest radiograph)/ND	Pseudomonas aeruginosa	Cured	Alive 2007 Sep 2

*Ct, cycle threshold; CT, computed tomography; BAL, bronchoalveolar lavage; ND, not done; NPA, nasopharyngeal aspirate; ALL, acute lymphoblastic leukemia; hRV, human rhinovirus; HCoV, human coronavirus; hMPV, human metapneumovirus; EBV, Epstein-Barr virus; GVHD, graft versus host disease; IFA, influenza virus A; JCV, JC polyomavirus; BKV, BK polyomavirus; AML, acute myeloblastic leukemia; PIV, parainfluenza virus; NA, not applicable; MV, mechanical ventilation;

 $\pm WBC < 0.5 \times 10^{9}/L.$

‡Patients with KIV positive stools

§Death due to GVHD, aspergillosis, and multiple organ failure.

Invasive pulmonary aspergillosis diagnosed 2007 Apr 4; former nodules on CT scan had resolved while new micronodules appeared in URL.

#Due to aspergillosis and transplant rejection.

**No new abnormability compared with known lung disease.